Ultrafast-acting insulins: state of the art - Wikidata - wikimedia - TriplyDB

Ultrafast-acting insulins: state of the art

Ultrafast-acting insulins: state of the art

http://www.wikidata.org/entity/Q38037727

about

[Fast-acting insulin - new developments towards more flexibility for the patient].Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin.Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies.Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.Modern insulins, old paradigms and pragmatism: choosing wisely when deciding how to treat type 1 diabetes.Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control.Undeniable need for ultrafast-acting insulin: the pediatric perspective Biosimilar Insulin and Costs: What Can We Expect?Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas.Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes.Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators.The Need for Faster Insulin.Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?Understanding concentrated insulins: a systematic review of randomized controlled trials.Pharmacological Properties of Faster-Acting Insulin Aspart.Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.

P2860

Q30313628-6F7DB409-727F-4580-85A3-6F5EE2B0FBE5 Q30418520-4BC80552-AA5D-4B2F-877B-57DCDA983C81 Q30653146-5ED1FDA7-20A7-4229-96F2-B8B9726B6FD3 Q33658772-EA4FD1B7-9112-4BBF-AE4C-9EA37DF2AC9F Q35590648-DFAF1D78-999A-4A56-95A8-15B02EFB291E Q35929406-9C14D21A-A94D-4507-9973-2F3692DED106 Q36158995-7E657A1E-6B2D-43DC-9E5C-764693CEC331 Q36229282-C8E2D2E7-864D-4D1C-8ABD-667BECCD76B1 Q36638889-0CA072AE-20CE-4BA5-8074-66378174C19C Q37320243-25825443-7AED-4DFF-BB2C-8D16E3B2078E Q37595832-3C850C0F-8E0B-4ACF-B72D-65F395D093A3 Q37633455-8FC110D9-5A0D-4A69-AB1A-EC0A80A5D583 Q37732207-56FCE910-7DCB-44AE-967C-7969CEB8092D Q37742600-B67BA8FE-2754-4020-A817-297B739A0DF9 Q38578266-227947F3-F12D-4728-B01A-E4A9CD8BCE6E Q38750029-E6ABC64B-F149-4ACC-B5AB-66056A6B0E3C Q41172888-C74EBEEE-93A0-41E6-AF91-B45D6A825010 Q41873997-01F8F9B5-A33E-42CF-9B2B-2F5F4EBDF87B Q43143808-E33BCFFC-7070-4FD4-BF1B-C721CE3B92B4 Q47226752-3CE58356-5C59-47A6-9705-05D2D82D83E7 Q47322851-DA6CBD1B-2B59-43C0-ACFA-419823B6C563 Q47937602-40970278-6E6B-464B-8BAD-E692C3FC9741 Q54943513-D1A4E1C3-2D59-4019-AEF0-7373367AC82D Q55431482-B4788486-35A1-4EA5-967D-A78FE5EE8B8A

P2860

Ultrafast-acting insulins: state of the art

http://www.wikidata.org/entity/Q38037727

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ultrafast-acting insulins: state of the art

@en

type

label

Ultrafast-acting insulins: state of the art

@en

prefLabel

Ultrafast-acting insulins: state of the art

@en

P1433

Q38037727-31079610-6734-4C2F-9401-6F84E7720E2A

P1476

Q38037727-5DB5DF5B-EE21-4FD3-9E94-349A17AA44E7

P2093

Q38037727-6A3E89EF-BE80-4833-B556-E022F1149A44

P2860

Q38037727-0169BC88-B12F-4959-8808-37F875F4564D

Q38037727-0364F9BF-6D84-499F-8AD8-20E4C355DEDD

Q38037727-0C13E657-C534-4F06-A5EB-6BF4ADAD995A

Q38037727-0E91449C-4C8E-4928-BB1E-7327DEBDBB8E

Q38037727-0F5230D6-32C4-4675-B38F-941464C969C9

Q38037727-10E32CD2-BD57-4F8B-A11A-2B9D645CEAE8

Q38037727-161DD9D7-E664-4DD5-8981-6517F0D6D259

Q38037727-181362F3-2726-4E70-B298-E69EE608F6F7

Q38037727-1AB54BC2-7295-4E69-B619-6071B6D0232D

Q38037727-2311FBAD-F787-4E14-AB75-D049E293EA38

P304

Q38037727-6FBA0E4E-1F3A-42EA-BD1F-37A7154EAB79

P31

Q38037727-A20D9F3E-BBCC-4F4D-8246-735A9E95961F

P356

Q38037727-E7BCEF44-4A53-4820-8648-6766485E3BAD

P433

Q38037727-FB6FD342-A3F6-4207-939E-730F2D24F961

P478

Q38037727-814DB4B2-BAE0-4C2C-80AB-72EA475D8A73

P50

Q38037727-65FA4020-8759-4CF1-B6C1-3BFA67467D81

P577

Q38037727-3DEF3D96-FB95-4D0D-AA86-7BC79B175F73

P5875

Q38037727-8215A34A-3881-41F1-8861-765B0982052E

P698

Q38037727-1CE5167D-4F2F-4EC4-8958-EB1812500581

P932

Q38037727-1B6A4257-2682-4904-AEDE-D2494C13849E

P356

193229681200600402

P1433

Journal of Diabetes Science and Technology

P1476

Ultrafast-acting insulins: state of the art

@en

P2093

Douglas B Muchmore

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions

A review of a family of ultra-rapid-acting insulins: formulation development

Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin.

Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial.

Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.

Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation.

Insulin bolus given by sprinkler needle: effect on absorption and glycaemic response to a meal.

Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes.

Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects

Delivery of insulin by jet injection: recent observations.

P304

728-742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/193229681200600402

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230740143

http://www.w3.org/2001/XMLSchema#string

P698

22920797

http://www.w3.org/2001/XMLSchema#string

P932

3440142

http://www.w3.org/2001/XMLSchema#string